We do it right.

FAQ'S

press question to open answer

• When was the company founded?

  The Company was founded in 2016, in the Israeli port city of Ashdod, based on the know-how and experience of the founding company Solbar Foods Ltd., Cannassure's majority shareholder.  

• How many employees does Cannassure Therapeutics have?

  The company currently has 25 full and part-time employees and contractors.

• When did the company become public?

  The company went public in December 2018 by an RTO with a shell company on the Tel Aviv Stock Exchange (TASE).

• On what exchange is the company traded?

  The company is traded on the Tel Aviv Stock Exchange (TASE) under the ticker symbol CSURE.

• Where can I find Cannassure's latest investor presentation?

  Cannassure's most recent investor presentation is available in the “Investors” section on the company’s website. Click here to access now.

• When is Cannassure’s fiscal year end?

  The fiscal year ends on December 31.

• Who is the majority shareholder?

  The major shareholder is Solbar Food Technologies Ltd, a privately held company owned by Nir Peles and Shimon Barkama, currently holding 65% of Cannassure Therapeutics shares. Hadassa Medical holds an 8-year warrant to 5% of the shares, effectively setting the controlling shareholder at 60%, 52% on a fully diluted basis.

• Does Cannassure pay dividends on its common stock?

  Cannassure has never declared or paid cash dividends. The company intends to retain future earnings for the operation and expansion of its business and does not anticipate paying any cash dividends in the foreseeable future.

• Who are Cannassure’s independent auditors?

  Cannassure's independent auditors are BDO Ziv Haft.

• Who is Cannasure’s legal counsel?

  Cannassure's legal council is ZAG – Zisman Aharony Gayer.

• How do I contact Cannasure’s Investor Relations?

  For any information regarding investor relations Please contact Cannassure CEO, Ran Amir. Email: Ran.Amir@cannassure.life